Cargando…
Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan
The serotonin receptor agonist triptan drugs (5-HT1B/1D receptor agonists) have been in use for over 20 years in the abortive management of migraine. Although clearly effective, their ability to produce vasoconstriction in cerebral and coronary arteries, thought to be mediated by their high affinity...
Autor principal: | Rizzoli, Paul B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976237/ https://www.ncbi.nlm.nih.gov/pubmed/24729708 http://dx.doi.org/10.2147/NDT.S25531 |
Ejemplares similares
-
The potential of lasmiditan in migraine
por: Mecklenburg, Jasper, et al.
Publicado: (2020) -
Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
por: Oswald, Jessica C, et al.
Publicado: (2018) -
Efficacy of lasmiditan for the acute treatment of perimenstrual migraine
por: MacGregor, E Anne, et al.
Publicado: (2022) -
ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020) -
Safety findings from Phase 3 lasmiditan studies for acute treatment
of migraine: Results from SAMURAI and SPARTAN
por: Krege, John H, et al.
Publicado: (2019)